288 related articles for article (PubMed ID: 14689374)
1. Improving the bacteriological safety of platelet transfusions.
Blajchman MA; Goldman M; Baeza F
Transfus Med Rev; 2004 Jan; 18(1):11-24. PubMed ID: 14689374
[TBL] [Abstract][Full Text] [Related]
2. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
3. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine.
Hillyer CD; Josephson CD; Blajchman MA; Vostal JG; Epstein JS; Goodman JL
Hematology Am Soc Hematol Educ Program; 2003; ():575-89. PubMed ID: 14633800
[TBL] [Abstract][Full Text] [Related]
4. Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis.
Corash L
Expert Rev Hematol; 2011 Oct; 4(5):509-25. PubMed ID: 21939419
[TBL] [Abstract][Full Text] [Related]
5. Improving the bacteriological safety of platelet transfusions.
Cid J; Lozano M
Transfus Med Rev; 2004 Jul; 18(3):235-6; author reply 236. PubMed ID: 15248173
[No Abstract] [Full Text] [Related]
6. Bacterial contamination of platelets for transfusion: strategies for prevention.
Levy JH; Neal MD; Herman JH
Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
[TBL] [Abstract][Full Text] [Related]
7. Bacterial detection of platelets: current problems and possible resolutions.
Blajchman MA; Beckers EA; Dickmeiss E; Lin L; Moore G; Muylle L
Transfus Med Rev; 2005 Oct; 19(4):259-72. PubMed ID: 16214015
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
9. Improving platelet safety: bacterial contamination of platelets.
Brecher ME; Hay SN
Curr Hematol Rep; 2004 Mar; 3(2):121-7. PubMed ID: 14965488
[TBL] [Abstract][Full Text] [Related]
10. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
11. Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients.
Klausen SS; Hervig T; Seghatchian J; Reikvam H
Transfus Apher Sci; 2014 Oct; 51(2):97-102. PubMed ID: 25242310
[TBL] [Abstract][Full Text] [Related]
12. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
13. Lack of efficacy for conventional gamma irradiation of platelet concentrates to abrogate bacterial growth.
Huston BM; Brecher ME; Bandarenko N
Am J Clin Pathol; 1998 Jun; 109(6):743-7. PubMed ID: 9620033
[TBL] [Abstract][Full Text] [Related]
14. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
15. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
[TBL] [Abstract][Full Text] [Related]
16. [Effects of use of riboflavin and ultraviolet light for pathogen inactivation on quality of platelet concentrates].
Stanojković Z; Antić A; Stojanović M
Vojnosanit Pregl; 2011 Jun; 68(6):489-94. PubMed ID: 21818915
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.
Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML
Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109
[TBL] [Abstract][Full Text] [Related]
18. Bacterial contamination of platelet concentrates: incidence, significance, and prevention.
Blajchman MA; Goldman M
Semin Hematol; 2001 Oct; 38(4 Suppl 11):20-6. PubMed ID: 11727282
[TBL] [Abstract][Full Text] [Related]
19. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk of bacterial contamination of cellular blood components.
Blajchman MA
Dev Biol (Basel); 2000; 102():183-93. PubMed ID: 10794105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
